What Happens Behind the Scenes Before an IVF Cycle Begins

This guide walks through what actually happens in the weeks and months before an IVF cycle begins, why each element matters, and what patients can usefully understand about this preparatory phase, both to set realistic expectations and to engage more actively in the process that precedes their treatment.

Table of Contents

• The Initial Assessment and Diagnostic Workup
• Ovarian Reserve Testing and What It Tells the Clinical Team
• Uterine Evaluation Before Treatment Begins
• Partner or Donor Assessment
• Genetic Screening and Counselling Considerations
• Designing the Stimulation Protocol
• Medications, Pharmacy Coordination, and Logistics
• Administrative Preparation and Informed Consent
• Lifestyle Preparation and Patient Readiness
• Timing the Cycle Start
• What Patients Can Do During the Preparatory Phase
• Frequently Asked Questions

The Initial Assessment and Diagnostic Workup

Before a stimulation protocol can be designed or a cycle start date discussed, the clinical team needs a clear picture of each patient’s baseline fertility status. The initial assessment phase is where that picture is assembled, drawing on blood tests, imaging, clinical history, and in some cases additional investigations that vary depending on the individual patient’s circumstances.

Why a Thorough Baseline Assessment Matters for What Follows

The stimulation protocol used in an IVF cycle, the medications chosen, the doses administered, and the targets the clinical team is aiming for are all calibrated to the individual patient’s baseline status. A protocol designed without adequate baseline assessment is one designed with incomplete information, which limits the clinical team’s ability to anticipate how the patient will respond and to intervene appropriately if the response deviates from what was expected.

Why This Phase Takes the Time It Does

Patients are sometimes surprised by how much time the pre-cycle workup takes before any active treatment begins. The reason is that the assessments performed during this phase are not administrative formalities. They are the clinical inputs that determine how treatment will be structured, and rushing them compromises the quality of what follows.

Blood Tests and Hormonal Baseline

A range of blood tests forms the foundation of the initial assessment. These typically include hormone levels measured at specific points in the menstrual cycle, thyroid function, and tests for infectious diseases required both for clinical reasons and by regulatory requirements. The precise panel varies between clinics and between patients, but the underlying purpose is consistent: to give the clinical team the hormonal and physiological baseline they need to plan treatment appropriately.

Ovarian Reserve Testing and What It Tells the Clinical Team

Ovarian reserve, a measure of the quantity and to some extent the quality of a patient’s remaining egg supply, is one of the most clinically significant pieces of information gathered before an IVF cycle. It shapes expectations for how the patient is likely to respond to stimulation and informs key decisions about protocol design.

Anti-Müllerian Hormone as a Key Marker

Anti-Müllerian hormone, commonly referred to as AMH, is produced by small follicles in the ovaries and provides one of the most reliable available indicators of ovarian reserve. A higher AMH level generally indicates a larger pool of available follicles and suggests the patient is likely to respond well to stimulation. A lower AMH level suggests a smaller pool, which may affect both protocol design and the expectations the clinical team and patient should hold about egg numbers.

Why AMH Is Informative but Not Definitive

AMH is a useful clinical tool, but it is not a precise predictor of treatment outcome. Two patients with similar AMH levels can respond differently to the same protocol, and AMH does not directly measure egg quality, which is a distinct and clinically significant dimension of fertility. The clinical team uses AMH as one input among several rather than as a standalone determinant of prognosis.

Antral Follicle Count and Ultrasound Assessment

An ultrasound performed early in the menstrual cycle allows the clinical team to count the antral follicles visible in each ovary. These small, early-stage follicles represent the cohort from which eggs will be recruited during stimulation. The antral follicle count, taken alongside AMH and other clinical information, helps the team anticipate how many follicles are likely to develop during the stimulation phase and calibrate medication doses accordingly.

What Low Ovarian Reserve Means for Pre-Cycle Planning

A patient with low ovarian reserve typically requires a different pre-cycle approach from one with a normal or high reserve. The clinical team may recommend a different stimulation protocol, different medication doses, or additional investigations to refine the approach. In some cases, the pre-cycle assessment reveals that IVF with the patient’s own eggs is unlikely to be successful, and the team will need to discuss alternative pathways before treatment begins.

Uterine Evaluation Before Treatment Begins

The uterus is where a successfully fertilised embryo must implant and develop, and its structure and condition matter significantly for IVF outcomes. A thorough uterine evaluation before the cycle begins is a standard part of pre-treatment preparation in most fertility clinics.

Saline Infusion Sonography and Hysteroscopy

Two common methods for evaluating the uterine cavity are saline infusion sonography, which uses a small amount of saline fluid introduced into the uterus to improve ultrasound visualisation of the cavity, and hysteroscopy, which involves passing a thin camera through the cervix to directly inspect the uterine interior. Both allow the clinical team to identify structural issues such as polyps, fibroids, or adhesions that might affect implantation if left unaddressed.

Why Identifying and Addressing Uterine Issues Before the Cycle Matters

A uterine abnormality identified and treated before a cycle begins does not necessarily affect that cycle’s outcome if treatment is completed in time. The same abnormality identified mid-cycle or after an implantation failure represents a missed opportunity to address a potentially correctable factor before a significant clinical and emotional investment was made. Pre-cycle uterine evaluation is therefore not only clinically valuable but also practically protective of the patient’s investment in the process.

Endometrial Receptivity Considerations

Beyond structural evaluation, some clinics conduct additional testing related to endometrial receptivity, the degree to which the uterine lining is prepared to receive and support an embryo. These tests are not universally indicated and their clinical value is an area of ongoing research, but they represent part of the expanding toolkit some clinics use to personalise the timing and approach of embryo transfer in advance of the cycle.

Partner or Donor Assessment

Where a partner’s sperm will be used in the IVF cycle, a semen analysis is a fundamental part of the pre-cycle workup. Where donor gametes, whether eggs or sperm, will be used, the assessment and selection process for donors is a distinct and significant preparatory step.

Semen Analysis and What It Evaluates

A semen analysis assesses several parameters of sperm quality, including concentration, motility, and morphology. The results inform decisions about the fertilisation method to be used, specifically whether standard insemination is appropriate or whether intracytoplasmic sperm injection, in which a single sperm is injected directly into an egg, is indicated by the sperm parameters observed.

Why Semen Analysis Before the Cycle Allows for Better Planning

A semen analysis result that indicates a significant male factor component changes the clinical plan in ways that are better addressed before the cycle begins than during it. If additional investigations are needed, such as a referral to a urologist or further sperm function testing, the pre-cycle window is the appropriate time for those steps, rather than discovering the issue when sperm is needed on the day of egg collection.

Donor Selection and Matching Where Applicable

For patients using donor eggs, donor sperm, or a combination of both, the selection and matching process is a preparatory step that can take considerable time and involves both clinical and personal dimensions. Clinics support patients through this process differently depending on whether they work with known or anonymous donors, whether they use their own donor pool or work with external banks, and what information and criteria are available to patients in the selection process.

Genetic Screening and Counselling Considerations

Genetic factors are an increasingly significant dimension of pre-cycle preparation in IVF, particularly as preimplantation genetic testing has become more widely available and more patients arrive with known or suspected genetic concerns.

Carrier Screening for Inherited Conditions

Carrier screening identifies whether one or both partners carry genetic variants associated with inherited conditions that could affect a child born from the treatment. Clinics vary in how routinely they offer or recommend carrier screening, but for patients with a known family history of heritable conditions, or for couples where both partners are from population groups with elevated carrier rates for specific conditions, the pre-cycle period is the appropriate time for this assessment.

Preimplantation Genetic Testing and Its Pre-Cycle Implications

For patients planning preimplantation genetic testing of embryos, either for chromosomal abnormalities or for specific genetic conditions, the decision to do so and the logistical arrangements it involves need to be made before the cycle begins. This includes confirming the testing laboratory, ensuring the clinical team has the protocols in place, and, where relevant, the design of specific probes for targeted genetic testing that may take several weeks to prepare.

Why the Decision to Test Cannot Wait Until the Cycle Is Underway

Preimplantation genetic testing requires embryos to be biopsied, typically at the blastocyst stage, and the biopsy samples sent to a specialist genetics laboratory. The logistics of this process, and in some cases the preparation of testing materials specific to the patient’s genetic concern, cannot be arranged in the days during an active stimulation cycle. Pre-cycle planning for genetic testing is therefore not optional for patients who wish to pursue it.

Genetic Counselling as Part of Pre-Cycle Preparation

Where genetic factors are part of the clinical picture, whether known or newly identified through pre-cycle screening, access to a genetic counsellor before the cycle begins allows patients to make genuinely informed decisions about their treatment pathway. This counselling addresses not just the clinical implications of genetic findings but the emotional and ethical dimensions that many patients need support navigating before they can move forward with confidence.

Designing the Stimulation Protocol

One of the most clinically significant decisions made before an IVF cycle begins is the design of the ovarian stimulation protocol. This decision synthesises the findings from the pre-cycle workup and reflects the clinical team’s judgment about how best to support the development of a cohort of mature eggs in this specific patient.

The Main Protocol Types and Why the Choice Matters

The two most commonly used broad approaches to ovarian stimulation are the long agonist protocol, in which the patient begins medication in the cycle before their IVF cycle to suppress natural hormone fluctuations, and the antagonist protocol, in which suppression medication is added during the stimulation phase itself. The choice between these, and the many variations within each category, depends on factors including the patient’s ovarian reserve, age, previous cycle history, and the clinical team’s assessment of the most appropriate approach for their individual profile.

Why Protocol Design Is Not Standardised Across Patients

There is no universally optimal IVF stimulation protocol. The clinical decisions involved in protocol design are judgments that balance the goal of obtaining a useful number of mature eggs against the risk of over-response, the patient’s clinical history, and the team’s experience with how patients with similar profiles have responded to different approaches. This is one of the reasons pre-cycle assessment is as detailed as it is: the quality of the protocol depends on the quality of the information it is built on.

Setting Stimulation Goals and Managing Expectations

As part of protocol design, the clinical team forms a view of what a successful stimulation response would look like for this patient, including the range of egg numbers they might realistically aim for and the factors that could cause the cycle to proceed differently from what was planned. Sharing this picture with the patient before the cycle begins is an important part of pre-cycle preparation, because it allows the patient to enter the stimulation phase with calibrated expectations rather than assumptions that may not match their clinical reality.

Medications, Pharmacy Coordination, and Logistics

The medications used in an IVF cycle are specialised, often expensive, and need to be sourced, coordinated, and ready before the cycle start date. The logistical work involved in this step is often invisible to patients but represents a significant administrative and coordination effort behind the scenes.

Prescribing and Insurance Authorisation

IVF medications must be prescribed by the treating clinician and, where applicable, submitted for insurance authorisation before they can be dispensed. The authorisation process can take time and may involve documentation requirements that the clinic’s administrative team manages on behalf of the patient. Where medication is not covered by insurance, the clinic may work with specialist pharmacies to find the most cost-effective sourcing options available.

Patient Education on Medication Administration

Before a cycle begins, patients need to understand how to administer their medications, including self-injection technique, storage requirements, timing, and what to do if they miss a dose or experience an unexpected reaction. This education is typically provided through a combination of written materials, video resources, and a dedicated appointment or nursing contact, and it needs to happen before the medication start date, not on the first day of injection.

Why Medication Education Is a Clinical Priority, Not an Administrative One

Errors in medication administration, whether incorrect timing, incorrect dose, or incorrect technique, can affect the cycle outcome in ways that cannot always be corrected once the stimulation phase is underway. Patient education on medication is therefore a clinical responsibility of the first order, not a box to check before the real treatment begins.

Administrative Preparation and Informed Consent

Alongside the clinical preparation, a significant amount of administrative work takes place before an IVF cycle begins, much of which is both legally required and clinically important in its own right.

Informed Consent as a Genuine Clinical Process

Informed consent for IVF involves more than signing a set of forms. Done properly, it is a process through which patients receive enough information about what the treatment involves, what the risks are, what the alternatives are, and what happens to embryos created in the process, to make a genuinely informed decision to proceed. This process takes time and requires that patients have an opportunity to ask questions, reflect, and, if they wish, seek additional information before committing.

Why Consent Cannot Be Meaningfully Obtained at the Last Minute

A consent process conducted immediately before a procedure, or in a context where the patient feels pressure to sign quickly in order to proceed, does not meet the standard of genuine informed consent. Pre-cycle consent processes that are conducted well in advance of the cycle start date, with time built in for questions and reflection, protect both the patient’s autonomy and the clinic’s clinical and legal standing.

Legal and Regulatory Requirements

IVF is subject to regulatory requirements that vary by jurisdiction but typically include requirements around consent for the creation, storage, and use of embryos, requirements around donor anonymity or disclosure depending on local law, and in some cases waiting periods between consent and treatment. The clinic’s administrative team manages compliance with these requirements, but patients benefit from understanding that they exist and that some of the pre-cycle timeline is shaped by legal requirements rather than purely clinical ones.

Lifestyle Preparation and Patient Readiness

The pre-cycle period is also the time during which patients are often advised to attend to lifestyle factors that may influence their cycle, and during which the emotional and psychological preparation for treatment takes shape.

Lifestyle Factors and Their Role in Pre-Cycle Preparation

Nutritional status, weight, smoking, alcohol consumption, and certain medications or supplements are all factors that fertility clinicians may raise during the pre-cycle period. The evidence base for specific lifestyle interventions in IVF is variable, and clinics differ in how prescriptively they address these factors, but the pre-cycle window is generally the appropriate time to address modifiable factors rather than attempting to make significant changes once stimulation has begun.

Psychological Readiness and Emotional Preparation

Entering an IVF cycle is a significant event in most patients’ lives, and the pre-cycle period is when much of the psychological preparation for what lies ahead takes place. Clinics that support patients through this preparation, whether through access to a counsellor, peer support resources, or simply through honest conversations about what the cycle experience is likely to involve, are better preparing their patients for the emotional demands of treatment than those that focus exclusively on clinical preparation.

Why Emotional Preparation Is Part of Clinical Preparation

A patient who enters a stimulation cycle with unrealistic expectations, unresolved anxiety about a specific aspect of the process, or inadequate support structures in place is not as well prepared for the cycle as one whose clinical markers are identical but whose psychological readiness is also attended to. The clinical and emotional dimensions of pre-cycle preparation are not separate tracks but interconnected aspects of the same readiness for treatment.

Timing the Cycle Start

The start of an IVF cycle is not an arbitrary date but a point in the patient’s cycle that is determined by both clinical and logistical factors, and coordinating that timing involves more behind-the-scenes work than most patients realise.

Cycle Synchronisation and Its Clinical Logic

In most protocols, the timing of the cycle start is coordinated with specific points in the patient’s menstrual cycle, sometimes using hormonal preparation to establish a predictable starting point. This coordination is not primarily a logistical convenience but a clinical decision about the optimal conditions under which to begin stimulation for this particular patient and protocol.

Laboratory and Clinical Team Scheduling

An IVF cycle requires the coordinated availability of the clinical team, the embryology laboratory, and the administrative infrastructure that supports them. Behind the scenes, the scheduling of a cycle involves confirming that laboratory capacity is available for the likely egg collection window, that the treating clinician and embryology team are accessible across the key dates of the cycle, and that any specialist procedures, such as surgical sperm retrieval or genetic testing, are arranged within the right timeframe.

Why Cycle Scheduling Is More Complex Than It Appears

From the patient’s perspective, a cycle start date is a single piece of information. Behind that date lies a coordination exercise that involves multiple clinical staff, a specialist laboratory, external service providers in some cases, and the inherent unpredictability of biological processes that do not always conform to the planned timeline. The administrative and clinical work of managing this coordination is one of the less visible but genuinely demanding aspects of what a fertility clinic does before a cycle begins.

What Patients Can Do During the Preparatory Phase

The pre-cycle phase is not purely passive for patients. There are things patients can actively do during this period that contribute meaningfully to their readiness for the cycle ahead.

Engaging Fully With the Assessment Process

Attending all recommended pre-cycle assessments, providing complete and accurate clinical history, and being forthcoming about medications, supplements, and lifestyle factors gives the clinical team the information they need to plan the cycle as effectively as possible. The quality of the clinical plan depends in part on the completeness of the information it is based on.

Asking Questions Before the Cycle Begins

The pre-cycle period is the right time to ask questions about the protocol, the medication schedule, what to expect during monitoring, what happens if the cycle does not go as planned, and anything else the patient needs to understand before treatment begins. Questions that arise once stimulation is underway are often harder to address in the time-pressured context of an active cycle, and patients who enter the stimulation phase with unanswered questions tend to experience more anxiety than those who have had the opportunity to resolve their uncertainties in advance.

Why No Question Is Too Basic to Ask Before a Cycle

Patients sometimes hesitate to ask questions they worry may seem too basic, or that they feel they should already know the answer to. The pre-cycle period is precisely the time when those questions should be asked and answered, because the clinical team’s goal during this phase is to ensure that the patient is as well prepared as possible for what follows. A question asked before the cycle is always better than a gap in understanding discovered during it.

Preparing Practically and Emotionally for the Cycle Ahead

Practical preparation, including arranging time off work for monitoring appointments and the egg collection procedure, planning for the emotional demands of the stimulation and waiting phases, and ensuring that adequate support is in place, is work that patients do best during the pre-cycle period rather than trying to arrange amid the time pressures of an active cycle.

Frequently Asked Questions

How long does the pre-cycle preparation phase typically take?

The timeline varies depending on the investigations required, the protocol chosen, and logistical factors including laboratory scheduling and, where applicable, insurance authorisation for medications. In many cases, the pre-cycle workup and preparation takes four to eight weeks from the initial assessment to the cycle start date, though this can be shorter or longer depending on individual circumstances.

Why are so many tests needed before an IVF cycle can begin?

The tests performed before an IVF cycle provide the clinical information on which the stimulation protocol, medication doses, and treatment approach are based. They also identify conditions that might affect the cycle outcome if left unaddressed. The quality and completeness of the pre-cycle assessment directly affects the quality of the clinical plan that follows.

What is ovarian reserve testing and why does it matter?

Ovarian reserve testing, typically including AMH blood testing and an antral follicle count ultrasound, provides an indication of the quantity of eggs remaining in the ovaries and helps the clinical team anticipate how a patient is likely to respond to stimulation medication. It is one of the most clinically significant pieces of information gathered before an IVF cycle.

Is a uterine evaluation always necessary before IVF?

Most fertility clinics recommend some form of uterine evaluation before a first IVF cycle to identify structural issues that might affect implantation. The specific method used varies between clinics and individual patients, but the underlying purpose is consistent: to ensure the uterine environment is as conducive as possible to implantation before the embryo transfer stage of treatment.

What happens if a genetic concern is identified during pre-cycle screening?

A genetic concern identified during pre-cycle screening is typically followed by referral to genetic counselling, where the clinical and personal implications can be explored and options including preimplantation genetic testing can be discussed. The pre-cycle period is the appropriate time for this process, as some genetic testing arrangements need to be established before the cycle begins.

Can patients make changes to their stimulation protocol before the cycle starts?

Patients are encouraged to discuss any concerns about their proposed protocol with their clinical team before the cycle begins. Protocol decisions are made collaboratively, and a patient who has questions or concerns about the approach recommended for their cycle should raise them during the pre-cycle consultation rather than after stimulation has started.

What should patients do if they receive their medications and are unsure how to use them?

Patients who have any uncertainty about their medication administration should contact their clinic before the medication start date rather than guessing or relying on general information sources. Clinics providing IVF treatment expect and are equipped to handle patient questions about medication, and there is no question too basic to ask before beginning a medication protocol.

Why does the cycle start date sometimes get delayed?

Cycle start dates can be delayed by a range of factors including the need for additional investigations, findings from pre-cycle assessment that require treatment before the cycle can proceed, scheduling constraints related to laboratory capacity or clinical team availability, or logistical factors such as medication authorisation timelines. Most delays, while frustrating for patients, reflect appropriate clinical caution rather than administrative failure.